杭州龙达新科生物制药

Hangzhou Longda Xinke Biopharmaceutical is a specialized Chinese biotechnology company focused on the production and development of recombinant protein therapeutics. Founded in 2004 and headquartered in Hangzhou, the company has established itself as a key provider of cytokines and growth factors within the domestic market. Its commercial portfolio features essential oncology support treatments, including recombinant human granulocyte colony-stimulating factor (rhG-CSF) for neutropenia and recombinant human interleukin-2 (rhIL-2) for various malignancies. The company operates advanced GMP-certified manufacturing lines and continues to focus on biological drugs that address critical needs in oncology, hematology, and infectious diseases.